Abstract
During the last five years, there has been enormous progress in molecular imaging and radionuclide therapy of prostate cancer. Two molecular imaging agents (11C-choline and 1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid [18F-FACBC]) ([1][1],[2][2]) and one radionuclide therapy (223Ra-dichloride
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
